Ronald Lieberman, MD
Emergency Medicine · Los Angeles, CANPI 1427004621
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 48 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AbbVie accounts for 62.1% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2022 at $244 and has fallen 60.8% since, to $96 in 2024. Among emergency medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 48 payments — averaging $15.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$466
- Pfizer$87
- AstraZeneca$57
- Irhythm Technologies, Inc.$48
- Johnson & Johnson$46
- Gilead$23
- plus $22 from 1 others
What the payments were for
- Food & beverage$750100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 33 | $466 |
| Pfizer | 5 | $87 |
| AstraZeneca | 3 | $57 |
| Irhythm Technologies, Inc. | 3 | $48 |
| Johnson & Johnson | 2 | $46 |
| Gilead | 1 | $23 |
| CSL Behring | 1 | $22 |
How this compares
$750 in reported general payments places this provider in the 90th percentile of 6,006 emergency medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Albuterol Sulfate HfaAlbuterol Sulfate | 13 | $391 |
| Ondansetron OdtOndansetron | 24 | $192 |
| Cephalexin | 33 | $130 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 17 | $81 |
| Prednisone | 21 | $31 |
Paid to pharmacies, not to this prescriber.
Other emergency medicine in Los Angeles
- Christopher PeabodyLos Angeles$163K
- Samuel BeckermanLos Angeles$81K
- Bharat KothakotaLos Angeles$51K
- Jay LeeLos Angeles$20K
- Anna Ryabets-LienhardLos Angeles$16K
- Michael BlueLone Pine$915K
- Andrew AccardiEncinitas$383K
- Fredrick Melik-AbrahamianSylmar$354K
- Graham WalkerStanford$309K
- Douglas WhiteOakland$220K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.